Full Press Release Details
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) --Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44thAnnual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website athttps://investors.dyne-tx.com/news-and-events/events-and-presentationsand a replay will be accessible for 30 days.
About Dyne TherapeuticsDyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn morehttps://www.dyne-tx.com/, and follow us onX,LinkedInandFacebook.Contacts: